

Issue Date: 5/20/1997.

Title: Nucleic Acid Probes and Methods for Detecting *Candida* DNA Cells in Blood.

U.S. Patent Application Serial No.: 08/065,845.

Filing Date: 5/20/1993.

Domestic Status: 5,426,027.

Issue Date: 6/20/1995.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

Specific DNA (oligonucleotide) probes have been developed for a wide variety of systemic disease causing fungi, including *Histoplasma capsulatum*, *Aspergillus* species, *Candida* species, *Fusarium* species, and others. A probe has been developed for identification of all dimorphic fungi. These probes can be used for the rapid identification of fungal pathogens and for the diagnosis of mycotic diseases.

ADDRESSES: Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to Andrew Watkins, Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; facsimile: (770) 488-8615. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within sixty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application.

Dated: March 31, 2003.

James D. Seligman,

Associate Director for Program Services,
Centers for Disease Control and Prevention
(CDC).

[FR Doc. 03-8322 Filed 4-4-03; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99F-2999]

Ciba Specialty Chemicals; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 9B4686) proposing that the food additive regulations be amended to provide for the safe use of benzenepropanoic acid, 3,5- bis(1,1-dimethylethyl)-4-hydroxy-, C7-C9-branched alkyl esters as an antioxidant and/or stabilizer for adhesives.

FOR FURTHER INFORMATION CONTACT:

Mark Hepp, Center for Food Safety and Applied Nutrition (HFS-275), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3858, 202-418-3098.

SUPPLEMENTARY INFORMATION: In a notice published in the *Federal Register* of September 7, 1999 (64 FR 48654), FDA announced that a food additive petition (FAP 9B4686) had been filed by Ciba Specialty Chemicals, 540 White Plains Rd., P.O. Box 2005, Tarrytown, NY 10591-9005. The petition proposed to amend the food additive regulations in § 178.2010 Antioxidants and/or stabilizers for polymers (21 CFR 178.2010) to provide for the safe use of benzenepropanoic acid, 3,5- bis(1,1-dimethylethyl)-4-hydroxy-, C7-C9-branched alkyl esters as an antioxidant and/or stabilizer for adhesives. Ciba Specialty Chemicals has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: March 20, 2003.

Alan M. Rulis,

Director, Office of Food Additive Safety,
Center for Food Safety and Applied Nutrition.

[FR Doc. 03-8335 Filed 4-4-03; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

[CFDA Number 93.110B]

Maternal and Child Health Federal Set-Aside Program; Special Projects of Regional and National Significance; Comprehensive Hemophilia Diagnostic and Treatment Centers; Regional Project Grant

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice of availability of funds.

SUMMARY: The Health Resources and Services Administration (HRSA) announces that \$360,000 in fiscal year (FY) 2003 funds is available to fund one grant to establish a regional network of hemophilia treatment centers (HTCs) in the Maternal and Child Health Bureau Hemophilia Program, Region IV North (Kentucky, North Carolina, South Carolina, and Tennessee) to provide comprehensive care for people with hemophilia and other congenital bleeding disorders and their families in the diagnosis and treatment of hemophilia and other bleeding disorders. This grant will be awarded for a 2-year period, subject to satisfactory progress and the availability of funds.

DATES: Applications must be received in the HRSA Grant Application Center (GAC) at the address below by the close of business, May 8, 2003. Applications will meet the deadline if they are either: (1) Received on or before the deadline date; or (2) postmarked on or before the deadline date, and received in time for submission to the objective review panel. A legible, dated receipt from a commercial carrier or U.S. Postal Service will be accepted instead of a postmark. Private metered postmarks will not be accepted as proof of timely mailing.

ADDRESSES: To receive a complete application kit, applicants may telephone the HRSA Grants Application Center at 1-877-477-2123 (1-877-HRSA-123) and present the announcement number HRSA 03-084 and announcement code HTC or register on-line at: <http://www.mchb.hrsa.gov/grants/>. All applications should be mailed or delivered to: Grants Management Officer (MCHB), HRSA Grants Application Center, 901 Russell Avenue, Suite 450, Gaithersburg, Maryland, 20879, telephone: 1-877-HRSA-123 (1-877-477-2123), e-mail: hrsagac@hrsa.gov.